BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III and Vulnerable Inflammation Parameter Registry

Trial Profile

BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III and Vulnerable Inflammation Parameter Registry

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms BIOFLOW-III
  • Sponsors BIOTRONIK
  • Most Recent Events

    • 29 Nov 2015 Planned End Date changed from 1 Dec 2018 to 1 May 2021.
    • 29 Nov 2015 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2018.
    • 29 Nov 2015 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top